Breast Cancer

Oncologic outcomes from a real-world analysis appear to be comparable with those observed in the sentinel lymph node biopsy arm of the SOUND trial.

The National Accreditation Program for Breast Centers looked at time intervals to see where delays occurred throughout the process for those with breast cancer.

Young patients with breast cancer were more likely to be the reason for diagnostic delays vs system delays, partly due to less concern for their symptoms.

Data from the NATALEE trial show that ribociclib may benefit a broad population of patients with early breast cancer who have an increased risk of recurrent disease.

Utidelone injection may cross the blood-brain barrier and help treat patients with breast cancer brain metastases.

Data from the phase 3 TROPION-Breast01 trial support the biologics license application for datopotamab deruxtecan in hormone receptor–positive, HER2-negative breast cancer.

Findings from the phase 3 CAPItello-291 trial support the approval of capivasertib/fulvestrant for patients with hormone receptor–positive, HER2-negative breast cancer in Japan.

Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.

Investigators will assess the PRE-ACT tool’s ability to predict adverse effects such as skin and heart damage in a phase 3 trial.

A Miami Breast Cancer Conference presentation focused on how the new ASTRO partial breast irradiation guidelines could be incorporated into practice.

Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.

Lymphedema is a common adverse effect and may negatively impact a patient’s body image.

Lymphedema is an adverse effect associated with breast cancer treatment, and patients should be monitored for these symptoms.

The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.

Targeted imaging and biopsy may accurately identify patients with breast cancer who do not have residual disease, according to Henry Kuerer, MD, PhD, FACS, CMQ.

The use of a robot to aid in nipple-sparing surgery has been a controversial topic, although ongoing trials may show its potential.

Reshma Jagsi, MD, DPhil, highlights disparities in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.

Findings from the INSITE trial support the Medical Imaging Drugs Advisory Committee’s positive opinion on pegulicianine for breast cancer surgery.

Findings from a phase 2 trial support the premise that activating the androgen receptor may elicit antitumor effects in patients with androgen receptor–positive, estrogen receptor–positive, HER2-negative breast cancer.

Heather Moore, CPP, PharmD, shares expert insights on the effective management of adverse effects related to tucatinib and other HER2 tyrosine kinase inhibitors (TKIs).

As the 41st Annual Miami Breast Cancer Conference approaches, Debu Tripathy, MD, prepares to step down as cochair.

A patient reported outcome analysis of the phase 3 OlympiA trial found that treatment-emergent symptoms were easily resolved after treatment with olaparib for BRCA1/2 high-risk HER2-negative breast cancer ended.

The National Comprehensive Cancer Network has issued a category 2A recommendation for the use of goserelin for ovarian function suppression in those with breast cancer.

Carey Anders, MD, offers insights into the BRIDGET trial, a study investigating the role of tucatinib in the prevention of secondary brain metastases in patients with advanced HER2-positive breast cancer.

Carey Anders, MD, examines strategies for treating stable and active brain metastases in individuals with advanced HER2-positive breast cancer, highlighting key data from the HER2CLIMB trial.

Carey Anders, MD, discusses the scenario of a 34-year-old patient diagnosed with HER2-positive breast cancer, who develops brain metastases after undergoing initial therapy with dual HER2 blockade.

Heather Moore, CPP, PharmD, presents a comprehensive summary of targeted therapies for HER2-positive breast cancer and provides expert insights into the management of adverse effects associated with these treatments.

Virginia Kaklamani, MD, offers clinical insights on treatment toxicity considerations in HR+ breast cancer, and the Oncology Brothers outline key takeaways from the discussion.

Medical oncologists provide comprehensive insights on the standard-of-care treatment practices for patients with advanced/metastatic HR+ breast cancer.

The Oncology Brothers and Virginia Kaklamani, MD, outline the treatment algorithm for patients with locally advanced HR+ breast cancer.